Everygene Launches No-Cost Genetic Testing for Cardiomyopathy with Broad Clinical Labs and Mass General Brigham
CAMBRIDGE, Mass., July 23, 2025 (Everygene) — Everygene launches no-cost genetic testing for cardiomyopathy patients, partnering with Broad Clinical Labs and Mass General Brigham to enhance diagnosis using advanced genomic technology.
Alloy Therapeutics and KSAC Announce Strategic Collaboration to Boost Japanese Biotech Startups
BOSTON, MA and TOKYO, JAPAN, July 22, 2025 (Alloy Therapeutics) — Alloy Japan and KSAC partner to boost Japanese life science startups with global biopharma support.
From Seattle to Chiba: Okayama University Taps AGC Biologics’ Global Pathway for New Therapeutic
SEATTLE, USA and CHIBA, Japan, July 17, 2025 (AGC Biologics) — Okayama University partners with AGC Biologics to develop a new therapeutic using CHEF1™ technology.
Alloy Therapeutics and Serbia’s BIO4 Campus Partner to Advance Global Bioeconomy and Biotech Innovation
Boston, MA, July 15, 2025 (Alloy Therapeutics) — Alloy Therapeutics partners with Serbia’s BIO4 Campus to advance biotech innovation and global bioeconomy.
AGC Biologics Expands Cell Therapy to Yokohama, Japan: CAR-T & Stem Cell Services
YOKOHAMA, Japan, June 25, 2025 (AGC Biologics) — AGC Biologics expands cell therapy operations to Asia at Yokohama Technical Center, enhancing global access to advanced therapies.
Roche Partners with Broad Clinical Labs on SBX Sequencing Technology for Neonatal Genetic Diagnosis
BURLINGTON, Mass., May 23, 2025 (Broad Clinical Labs) — Roche announces strategic collaboration with Broad Clinical Labs to develop groundbreaking applications using SBX sequencing technology, targeting rapid genetic diagnosis for critically ill newborns in neonatal intensive care units.
Candel Therapeutics’ CAN-2409 Shows 30% Reduction in Prostate Cancer Recurrence – Phase 3 Results at ASCO 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics reveals breakthrough Phase 3 results for CAN-2409 prostate cancer treatment, demonstrating significant reduction in disease recurrence and pathological complete response rates ahead of ASCO 2025 presentation.
Governor Abbott Announces NTxBio Facility In Plano
PLANO, Texas., May 15 /ntxbio.com/ — Governor Abbott announces NTxBio’s major expansion into Plano with a $31 million biomanufacturing facility creating over 170 jobs, supported by Texas Enterprise Fund investment to strengthen the state’s life sciences sector.
Oligo Factory Launches Low-Scale Oligo Synthesis Capability to Broaden Support for Therapeutic and Diagnostic Researchers and Developers
HOLLISTON, Mass., May 19, 2025 /Oligo Factory Communications/ — Oligo Factory launches new low-scale oligo synthesis capability, enabling researchers to order custom DNA and RNA oligonucleotides at volumes as low as 50 nmol while maintaining high quality and service standards. The company also introduces its FactorTx™ portfolio to support therapeutic development from discovery through clinical phases.
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24 /PRNewswire/ — Sermonix Pharmaceuticals and Regor Therapeutics Group have entered a strategic collaboration. The partnership will utilize Regor’s rCARD™ platform to identify novel targets and therapeutics for metastatic breast cancer, aiming for treatments that balance efficacy with tolerability and quality of life.